Race Oncology is a clinical-stage biotechnology enterprise dedicated to improving patient outcomes by developing innovative cancer treatments centered around its lead drug candidate, bisantrene (including its novel RC220 formulation). The company's research investigates mechanisms like G-quadruplex binding and conducts human clinical trials—such as studies targeting relapsed or refractory acute myeloid leukemia and advanced solid tumors—to reduce cardiotoxicity and enhance anti-cancer efficacy.